Phathom Pharmaceuticals Inc (NAS:PHAT)
$ 10.29 -0.21 (-2%) Market Cap: 602.33 Mil Enterprise Value: 442.44 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 30/100

Phathom Pharmaceuticals Inc Conference call on the PHALCON-EE Trial Results Transcript

Oct 18, 2021 / 12:30PM GMT
Release Date Price: $27.26 (-16.15%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Phathom Pharmaceuticals Phase III PHALCON-EE top line trial results conference call. (Operator Instructions)

I would now like to hand the call over to Joe Hand. Thank you. Please go ahead, sir.

Joseph Hand
Phathom Pharmaceuticals, Inc. - Chief Administrative Officer

Good morning, and thank you for joining us. My name is Joe Hand, and I'm Phathom's Chief Administrative Officer. We're excited to discuss the results from our PHALCON-EE Phase III erosive esophagitis trial that we shared earlier and to answer questions you have regarding the data. At the end of today's presentation, we will hold a Q&A session with Terrie Curran, our President and Chief Executive Officer; Azmi Nabulsi, our Chief Operating Officer; Martin Gilligan, our Chief Commercial Officer; and Tom Harris, our Senior Vice President, Regulatory Affairs.

As a reminder, matters covered in today's presentation, including the accompanying slides, include forward-looking statements. Such statements involve risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot